WASHINGTON UNIVERSITY 13F: Quarter-over-Quarter Portfolio Changes
WASHINGTON UNIVERSITY reported a disclosed portfolio value of approximately $264.8 million in its latest SEC Form 13F-HR filing for Q2 2026, up 65.3% quarter on quarter. Over the quarter, the endowment initiated 2 new positions and exited 1 position.
WASHINGTON UNIVERSITY's top buy was a new stake in Cerebras Systems INC (CBRS) , equal to 46.0% of the disclosed portfolio. Its top sell was Maze Therapeutics INC (MAZE) . The endowment exited the position completely after it had accounted for 5.2% of the previous portfolio.
New PositionsQ2 2026
Securities disclosed for the first time in Q2 2026 that were not present in the prior 13F-HR filing.
| Company | Ticker | Initial Portfolio Weight | History |
|---|---|---|---|
| CEREBRAS SYSTEMS INC | CBRS | 46.0% | History → |
| RUBRIK INC | RBRK | 0.7% | History → |
Full ExitsQ2 2026
Positions present in the prior 13F-HR filing that no longer appear in Q2 2026.
| Company | Ticker | Last-Reported Portfolio Weight |
|---|---|---|
| MAZE THERAPEUTICS INC | MAZE | 5.2% |
Net Portfolio Value ChangeQ2 2026
- $0.2BPrior quarter
- $0.3BCurrent quarter
- +$0.1BNet delta
- +65.3%% change
Methodology & FAQ
How WASHINGTON UNIVERSITY Quarterly Changes Are Computed
All deltas are sourced from sequential SEC Form 13F-HR filings for WASHINGTON UNIVERSITY: each row joins the most recent filing against the immediately preceding quarterly filing for the same fund. Share-count changes reflect reported trading activity, while portfolio weights can also move because of market price changes. Portfolio weights are normalized to exclude listed options for comparability. A complete description — including how confidential treatment filings are handled — is documented in the Methodology.
What stocks did WASHINGTON UNIVERSITY buy in Q2 2026?
In Q2 2026, WASHINGTON UNIVERSITY initiated 2 new positions (CEREBRAS SYSTEMS INC (CBRS), RUBRIK INC (RBRK)).
What stocks did WASHINGTON UNIVERSITY sell in Q2 2026?
In Q2 2026, WASHINGTON UNIVERSITY fully sold 1 position (MAZE THERAPEUTICS INC (MAZE)).
Which positions did WASHINGTON UNIVERSITY initiate in Q2 2026?
WASHINGTON UNIVERSITY established 2 new positions in Q2 2026: CEREBRAS SYSTEMS INC (CBRS, 46.0%), RUBRIK INC (RBRK, 0.7%).
Which existing positions saw the largest allocation increases for WASHINGTON UNIVERSITY in Q2 2026?
WASHINGTON UNIVERSITY reported no material allocation increases in existing positions in Q2 2026.
Which positions did WASHINGTON UNIVERSITY fully exit in Q2 2026?
WASHINGTON UNIVERSITY fully exited 1 position in Q2 2026: MAZE THERAPEUTICS INC (MAZE, last-reported weight 5.2%).
Which existing positions saw the largest allocation reductions for WASHINGTON UNIVERSITY in Q2 2026?
WASHINGTON UNIVERSITY reported no material allocation reductions in existing positions in Q2 2026.
Do quarter-over-quarter 13F allocation changes constitute explicit trading signals?
No. Quarter-over-quarter changes reflect a combination of active trading and market price movement. A weight increase can result from price appreciation alone, without the manager adding shares. Share-count delta is the cleaner indicator of explicit trading activity. All deltas on this page are sourced from sequential SEC Form 13F-HR filings.